- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- BIOCON LTD - ALEMBIC LTD
BIOCON LTD vs ALEMBIC LTD - Comparison Results
BIOCON LTD 
Change
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
ALEMBIC LTD
Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More
Current Valuations
| BIOCON LTD | ALEMBIC LTD | BIOCON LTD/ ALEMBIC LTD |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 82.6 | 57.0 | 144.9% | View Chart |
| P/BV | x | 7.0 | 2.4 | 294.0% | View Chart |
| Dividend Yield | % | 0.2 | 0.4 | 38.6% |
Financials
 BIOCON LTD  ALEMBIC LTD |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| BIOCON LTD Mar-18 |
ALEMBIC LTD Mar-18 |
BIOCON LTD/ ALEMBIC LTD |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,188 | 72 | 1,650.0% | |
| Low | Rs | 305 | 34 | 899.7% | |
| Sales per share (Unadj.) | Rs | 68.7 | 4.7 | 1,462.0% | |
| Earnings per share (Unadj.) | Rs | 7.6 | 6.1 | 123.7% | |
| Cash flow per share (Unadj.) | Rs | 14.0 | 6.2 | 223.7% | |
| Dividends per share (Unadj.) | Rs | 1.00 | 0.20 | 500.0% | |
| Dividend yield (eoy) | % | 0.1 | 0.4 | 35.5% | |
| Book value per share (Unadj.) | Rs | 86.3 | 40.7 | 212.4% | |
| Shares outstanding (eoy) | m | 600.00 | 267.03 | 224.7% | |
| Bonus/Rights/Conversions | IS | - | - | ||
| Price / Sales ratio | x | 10.9 | 11.3 | 96.4% | |
| Avg P/E ratio | x | 98.9 | 8.7 | 1,139.5% | |
| P/CF ratio (eoy) | x | 53.4 | 8.5 | 630.2% | |
| Price / Book Value ratio | x | 8.6 | 1.3 | 663.9% | |
| Dividend payout | % | 13.2 | 3.3 | 404.1% | |
| Avg Mkt Cap | Rs m | 447,900 | 14,139 | 3,167.8% | |
| No. of employees | `000 | 6.1 | NA | - | |
| Total wages/salary | Rs m | 9,311 | 207 | 4,489.4% | |
| Avg. sales/employee | Rs Th | 6,705.8 | NM | - | |
| Avg. wages/employee | Rs Th | 1,514.2 | NM | - | |
| Avg. net profit/employee | Rs Th | 736.9 | NM | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 41,234 | 1,255 | 3,285.1% | |
| Other income | Rs m | 2,062 | 370 | 557.0% | |
| Total revenues | Rs m | 43,296 | 1,625 | 2,663.7% | |
| Gross profit | Rs m | 8,291 | 111 | 7,462.6% | |
| Depreciation | Rs m | 3,851 | 38 | 10,187.8% | |
| Interest | Rs m | 615 | 2 | 36,176.5% | |
| Profit before tax | Rs m | 5,887 | 442 | 1,332.5% | |
| Minority Interest | Rs m | 213 | 0 | - | |
| Prior Period Items | Rs m | 0 | 1,212 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,569 | 24 | 6,551.1% | |
| Profit after tax | Rs m | 4,531 | 1,630 | 278.0% | |
| Gross profit margin | % | 20.1 | 8.9 | 227.2% | |
| Effective tax rate | % | 26.7 | 5.4 | 491.6% | |
| Net profit margin | % | 11.0 | 129.8 | 8.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 41,486 | 1,867 | 2,221.9% | |
| Current liabilities | Rs m | 21,413 | 591 | 3,622.0% | |
| Net working cap to sales | % | 48.7 | 101.6 | 47.9% | |
| Current ratio | x | 1.9 | 3.2 | 61.3% | |
| Inventory Days | Days | 64 | 94 | 67.9% | |
| Debtors Days | Days | 94 | 74 | 128.1% | |
| Net fixed assets | Rs m | 50,661 | 1,791 | 2,828.8% | |
| Share capital | Rs m | 3,000 | 534 | 561.7% | |
| "Free" reserves | Rs m | 48,808 | 10,324 | 472.8% | |
| Net worth | Rs m | 51,808 | 10,858 | 477.2% | |
| Long term debt | Rs m | 17,898 | 41 | 43,441.7% | |
| Total assets | Rs m | 99,897 | 11,591 | 861.9% | |
| Interest coverage | x | 10.6 | 260.9 | 4.1% | |
| Debt to equity ratio | x | 0.3 | 0 | 9,104.3% | |
| Sales to assets ratio | x | 0.4 | 0.1 | 381.1% | |
| Return on assets | % | 5.2 | 14.1 | 36.6% | |
| Return on equity | % | 8.7 | 15.0 | 58.3% | |
| Return on capital | % | 9.6 | 15.2 | 63.4% | |
| Exports to sales | % | 0 | 1.5 | 0.0% | |
| Imports to sales | % | 0 | 21.0 | 0.0% | |
| Exports (fob) | Rs m | NA | 19 | 0.0% | |
| Imports (cif) | Rs m | NA | 263 | 0.0% | |
| Fx inflow | Rs m | 12,058 | 19 | 62,154.6% | |
| Fx outflow | Rs m | 7,348 | 264 | 2,785.2% | |
| Net fx | Rs m | 4,710 | -244 | -1,927.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 6,621 | 236 | 2,807.9% | |
| From Investments | Rs m | -6,840 | -224 | 3,053.6% | |
| From Financial Activity | Rs m | -2,397 | -27 | 9,011.3% | |
| Net Cashflow | Rs m | -2,612 | -15 | 17,648.6% | |
Share Holding
| Indian Promoters | % | 40.4 | 64.0 | 63.1% | |
| Foreign collaborators | % | 20.6 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.4 | 0.2 | 4,200.0% | |
| FIIs | % | 10.7 | 9.7 | 110.3% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 19.9 | 26.1 | 76.2% | |
| Shareholders | 109,995 | 54,701 | 201.1% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON LTD With: ELDER PHARMA FDC LTD. SHASUN PHARMA FRESENIUS KABI ONCO. TTK HEALTHCARE
Compare BIOCON LTD With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Nifty Hits Fresh Record High; Sensex Up Over 330 Points(12:30 pm)
After opening the day on a positive note, stock markets in India continued their momentum and went on to scale their record-high levels.
Related Views on News
ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)
Aug 10, 2018 | Updated on Aug 10, 2018For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)
Jul 30, 2018 | Updated on Jul 30, 2018For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)
Aug 8, 2018Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why
Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)
Aug 9, 2018Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...
Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)
Aug 16, 2018While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)
Aug 8, 2018PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.
More|
| |
BIOCON LTD SHARE PRICE
Aug 20, 2018 02:13 PM
TRACK BIOCON LTD
- Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON LTD
BIOCON LTD 8-QTR ANALYSIS
COMPARE BIOCON LTD WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.